MLN1202 Placebo

DRUG2 trials

Sponsors

Takeda

Conditions

Diabetic NephropathyHealthy Japanese and Caucasian Male Adults

Phase 1

Phase 1 Single Subcutaneous Dose Study of MLN1202

WithdrawnNCT02426021

TakedaHealthy Japanese and Caucasian Male Adults

Start: 2015-04-30End: 2015-11-30Updated: 2016-10-27

Phase 2

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

WithdrawnNCT02410499

TakedaDiabetic Nephropathy

Start: 2015-05-20End: 2015-11-17Updated: 2017-09-25